Chronic kidney disease affects one-in-seven adults and is the ninth leading cause of death in the United States. A new Stanford-led study now provides clinicians with a powerful, cost-effective treatment for their patients with renal disease.
Stanford Health Policy celebrated the launch of the new Department of Health Policy on Sept. 1, 2021, as well as SHP Director Douglas K. Owens being named inaugural chair of the 13th basic sciences department within the School of Medicine.
The Veterans Administration is the largest provider of opioid use disorder treatment in the United States. In new Stanford Health Policy research, PhD student Jack Ching and faculty find short-term treatment with medication could yield big benefits.
A national body of evidence-based health experts — including SHP Director Douglas K. Owens — recommends screening for colon cancer in adults 45 to 75 in an effort to protect Americans from the third leading cause of cancer death in the country.
A Stanford team of decision scientists with colleagues at the VA Palo Alto Health Care System developed a mathematical model to assess the cost-effectiveness of various interventions to treat opioid use disorder. They looked at the cost-effectiveness from two perspectives: the health-care sector and the criminal justice system.
Most Americans think colorectal cancer is a disease of the elderly. But more young people — particularly Black men and women — are falling to the country's third deadliest type of cancer. The U.S. Preventive Services Task Force hopes to change that by lowering the age of routine testing to 45.
The CDC called on the National Academies of Sciences, Engineering and Medicine to develop a set of national, evidence-based guidelines for public health emergency preparedness and response. The recommendations are in.
A new study by Stanford researchers indicates adding cardiac resynchronization therapy to an implanted cardio defibrillator (CRT-D) for patients with mild heart failure may increase the quality of life and do so cost-effectively.
Eran Bendavid says the results of his work are a departure from a previous study. Earlier research found giving preventative drugs to large groups of gay men at high risk for HIV was not cost-effective when compared with other commonly accepted programs.